drugset / Trial / NCT04091061
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
Timeline
- Start
- 2019-10-03
- Primary completion
- 2020-04-07
- Completion
- 2020-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-06865571 | Small molecule | 100 mg | Oral |
Indications
No indication recorded.